At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Psilocybin therapydrug
Likely dose
Psilocybin therapy 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
In Brief
A Phase 2 clinical trial evaluating Psilocybin therapy for Parkinson Disease and 2 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Depression, Anxiety
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartAug 2021
Primary CompletionDec 2024
TodayJul 2026
First PostedJun 21, 2021
Enrollment StartAug 15, 2021
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.0 years ago
Interventions
Psilocybin therapydrug
* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring * Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring